News

b

b

Current News in Drug Discovery

RSS feed: Nature Reviews Drug Discovery Nature Reviews Drug Discovery
  • Selective oestrogen receptor degrader class grows with new cancer approval September 11, 2026
    Nature Reviews Drug Discovery, Published online: 11 September 2026; doi:10.1038/d41573-026-00151-0Selective oestrogen receptor degrader class grows with new cancer approval
    Asher Mullard
  • A translational framework for extrahepatic oligonucleotide delivery September 9, 2026
    Nature Reviews Drug Discovery, Published online: 09 September 2026; doi:10.1038/d41573-026-00125-2To unlock the ‘plug-and-play’ potential of extrahepatic delivery of oligonucleotide-based drugs, the field must bridge the gap between preclinical promise and clinical reality. Here, we outline an industry-grade quality framework to eliminate methodological artifacts and ensure the translational and commercial viability of novel platforms.
    Łukasz Jan Kiełpiński
  • Upcoming FDA approval decisions in Q4 2026 September 9, 2026
    Nature Reviews Drug Discovery, Published online: 09 September 2026; doi:10.1038/d41573-026-00150-1Upcoming FDA approval decisions in Q4 2026
    Kaniaw Dilzer
  • Un-siloed biomedical opportunities September 7, 2026
    Nature Reviews Drug Discovery, Published online: 07 September 2026; doi:10.1038/d41573-026-00148-9Edith Heard, CEO of the Francis Crick Institute, discusses the need to break down biomedical boundaries.
    Asher Mullard
  • Strengthening muscle for healthy ageing: innovative treatments for sarcopenia September 7, 2026
    Nature Reviews Drug Discovery, Published online: 07 September 2026; doi:10.1038/s41573-026-01514-3There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and metabolic mechanisms driving muscle wasting with ageing, while assessing emerging therapeutic approaches and agents in development.
    Sara Ancel
  • Newest glue degrader nabs multiple myeloma approval September 4, 2026
    Nature Reviews Drug Discovery, Published online: 04 September 2026; doi:10.1038/d41573-026-00147-wNewest glue degrader nabs multiple myeloma approval
    Asher Mullard
  • Click chemistry platform enhances ADC tumour targeting September 2, 2026
    Nature Reviews Drug Discovery, Published online: 02 September 2026; doi:10.1038/d41573-026-00146-xClick chemistry platform enhances ADC tumour targeting
    Alex Eccleston
  • Solute carrier membrane transporters: emerging targets in CNS disorders September 1, 2026
    Nature Reviews Drug Discovery, Published online: 01 September 2026; doi:10.1038/s41573-026-01513-4Solute carrier transporters are critical for maintaining central nervous system homeostasis, and their dysregulation is implicated in neurological diseases. This Review discusses the roles of solute carriers in neurodegenerative diseases, autism spectrum disorders and epilepsy, highlighting therapeutic strategies to modulate their activity, emerging technologies and tools […]
    Yee Kwan Law

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia™.

Attending on behalf of Vitreon America™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America™ was established with the goal of commercializing their Botanicopeia™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com